1 |
Glousker G, Touzot F, Revy P, Tzfati Y, Savage SA. Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder. Br J Haematol 2015;170:457-71.
DOI
|
2 |
Ohga S, Kai T, Honda K, Nakayama H, Inamitsu T, Ueda K. What are the essential symptoms in the Hoyeraal-Hreidarsson syndrome? Eur J Pediatr 1997; 156:80-1.
|
3 |
Islam A, Rafiq S, Kirwan M, Walne A, Cavenagh J, Vulliamy T, et al. Haematological recovery in dyskeratosis congenita patients treated with danazol. Br J Haematol 2013;162:854-6.
DOI
|
4 |
Khincha PP, Wentzensen IM, Giri N, Alter BP, Savage SA. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol 2014;165:349-57.
DOI
|
5 |
Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev 2010;24:101-22.
DOI
|
6 |
Pavlatos AM, Fultz O, Monberg MJ, Vootkur A, Pharmd. Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther 2001;23:789-801; discussion 771.
DOI
|
7 |
Brown KE, Kelly TE, Myers BM. Gastrointestinal involvement in a woman with dyskeratosis congenita. Dig Dis Sci 1993;38:181-4.
DOI
|
8 |
Andriole GL, Brickman C, Lack EE, Sesterhenn IA, Javadpour N, Linehan WM, et al. Danazol-induced cystitis: an undescribed source of hematuria in patients with hereditary angioneurotic edema. J Urol 1986; 135:44-6.
DOI
|